Bone Marrow Findings of Idiopathic Multicentric Castleman Disease: A Histopathologic Analysis and Systematic Literature Review
Overview
Authors
Affiliations
Idiopathic multicentric Castleman disease (iMCD) is a polyclonal lymphoproliferative disorder characterized by constitutional symptoms, generalized lymphadenopathy, cytopenias, and multi-organ dysfunction due to excessive cytokines, notably Interleukin-6. Idiopathic multicentric Castleman disease is often sub-classified into iMCD-TAFRO, which is associated with thrombocytopenia (T), anasarca (A), fever/elevated C-reactive protein (F), renal dysfunction (R), and organomegaly (O), and iMCD not otherwise specified (iMCD-NOS), which is typically associated with thrombocytosis and hypergammaglobulinemia. The diagnosis of iMCD is challenging as consensus clinico-pathological diagnostic criteria were only recently established and include several non-specific lymph node histopathological features. Identification of further clinico-pathological features commonly found in iMCD could contribute to more accurate and timely diagnoses. We set out to characterize bone marrow (BM) histopathological features in iMCD, assess differences between iMCD-TAFRO and iMCD-NOS, and determine if these findings are specific to iMCD. Examination of BM specimens from 24 iMCD patients revealed a high proportion with hypercellularity, megakaryocytic atypia, reticulin fibrosis, and plasmacytosis across patients with both iMCD-NOS and iMCD-TAFRO with significantly more megakaryocytic hyperplasia (p = 0.001) in the iMCD-TAFRO cases. These findings were also consistent with BM findings from 185 published cases of iMCD-NOS and iMCD-TAFRO. However, these findings are relatively nonspecific as they can be seen in various other infectious, malignant, and autoimmune diseases.
Miura K, Nishimaki-Watanabe H, Takahashi H, Nakagawa M, Otake S, Hamada T Biomedicines. 2024; 12(6).
PMID: 38927484 PMC: 11200895. DOI: 10.3390/biomedicines12061277.
Rubenstein A, Pierson S, Shyamsundar S, Sarmiento Bustamante M, Gonzalez M, Milller I Br J Haematol. 2024; 204(3):921-930.
PMID: 38168727 PMC: 10998476. DOI: 10.1111/bjh.19279.
Zinzani P, Paulli M, Arcaini L, Della Torre E, Ferrero S, Figuera A Hemasphere. 2023; 7(6):e891.
PMID: 37234822 PMC: 10208718. DOI: 10.1097/HS9.0000000000000891.
Idiopathic Multicentric Castleman Disease Occurring Shortly after mRNA SARS-CoV-2 Vaccine.
Hoffmann C, Wechselberger T, Drexel H, Dertinger S, Dirnhofer S, Pierson S Vaccines (Basel). 2022; 10(10).
PMID: 36298590 PMC: 9609308. DOI: 10.3390/vaccines10101725.
How we manage idiopathic multicentric Castleman disease.
Brandstadter J, Fajgenbaum D Clin Adv Hematol Oncol. 2022; 20(9):564-571.
PMID: 36125948 PMC: 9584165.